key: cord-0021181-nwgdim30
authors: van Gassel, Rob J. J.; Bels, Julia L. M.; Gietema, Hester A.; Posthuma, Rein
title: Reply to Vijayakumar and Shah
date: 2021-06-01
journal: nan
DOI: 10.1164/rccm.202102-0468le
sha: 37ed4ff7c060971fdc70dbd6ddd243bafbba027b
doc_id: 21181
cord_uid: nwgdim30

nan

with caution, they suggest that these lesions evolve either from affected areas showing a vacuole sign or from unaffected areas without infiltration or destruction. Thus, we agree that these new lesions may not be COVID-19 specific but rather a consequence of acute respiratory distress syndrome severity and/or ventilatorinduced injury.

The etiology of ground-glass opacifications, either inflammatory or fibrotic, may indeed be of relevance for therapeutic intervention and further recovery. Radiological follow-up to assess their evolution over time will be key to address this issue.

The 6-minute-walk test (6MWT) represents an integrated measure of both cardiopulmonary and skeletal muscle function (3), the latter likely being an equally significant contributor to impaired 6MWT results. The four patients in our cohort with significant (.4%) desaturation during the 6MWT were similarly affected in terms of pulmonary function test, HRCT results, and self-reported shortness of breath.

Small airway disease was indirectly assessed by the presence of air trapping on the expiration HRCT scan (4). Although many patients showed some air trapping, defined as more than 2-3 secondary lobules per lobe, the extent of air trapping was limited. Furthermore, we had no previous expiration CT scans in this study cohort, so we were not able to judge this finding as new. In contrast to its prevalence, the extent of air trapping was limited. This is in agreement with the absence of reversibility in pulmonary function test: no significant effect of bronchodilation on either FEV 1 We appreciate the remarks of Vijayakumar and Shah, which in our view highlight two key challenges that remain to be addressed in future work: 1) the long-term follow-up of these respiratory sequelae and their evolution/persistence over time and 2) unraveling the role of (micro)thrombosis in the respiratory sequelae as observed in survivors of COVID-19.

To the Editor:

We read with great interest the review article by Dr. Wenzel (1) . The author has well illustrated the importance of the asthma phenotype and endotype, and biomarkers and the role of advances in this area in biologically targeted therapies, especially in type 2 (T2)-high severe asthma. In this report, the author stated that integrated approaches, including clinical and molecular phenotyping, regarding responses to biological therapy significantly improved our understanding of phenotypes and even endotypes of severe asthma (1). We would like to thank Dr. Wenzel for her contribution to the literature with such a valuable review. We also would like to share our opinions on this report.

In clinical practice, inexpensive and easily accessible biomarkers and observable clinical conditions are used for the T2 asthma phenotype, which can reflect the T2 asthma endotype. We can think of it as the visible side of an iceberg. The Global Initiative for Asthma main report defined the T2 asthma phenotype by one or more of the following features: skin prick test against aeroallergens and/or specific IgE positivity, blood eosinophilia, sputum eosinophilia, fractionated exhaled nitric oxide elevation, and oral corticosteroid dependence (2) .

The association of phenotypes of asthma, which is quite heterogeneous, with cellular, molecular, immunological, and pathophysiological mechanisms is called endotype (3, 4) . We can think of it as the invisible side of an iceberg. T-helper cell type 2 (Th2) and IgE, and innate lymphoid cell 2 (ILC2) and IL-5-IL-13 pathways, play a role in the T2 asthma endotype (5, 6). In the Th2 and IgE-dominant subendotype of the T2 asthma endotype, in the presence of coactivators such as alarmins (TSLP, IL-33, and IL-25) released from the epithelium, Th2 cells of the adaptive immune response are stimulated by dendritic cells, and as a result, they produce IL-4, IL-5, and IL-13 (5, 7). IL-5 is an essential cytokine for the proliferation, survival, maturation, and activity of eosinophils. Both IL-4 and IL-13 induce IgE switching and IgE synthesis by B cells activated by CD4 1 T cells. The allergenspecific IgEs lead to mast cell activation by binding to the Fc«R1 receptors on mast cells, thus revealing early-and latephase allergic inflammation. In addition, these cytokines contribute to the migration of inflammatory cells to the airway, bronchial hyperreactivity, and airway remodeling (5, 7). In the ILC2-dominant subendotype of the T2 asthma endotype, epithelial-derived alarmins released after epithelial damage caused by toxins (especially Staphylococcal enterotoxins), irritants, aeroallergens, and microorganisms activate ILC2. IL-5 and IL-13 are produced in response to prostaglandin D2 by PGD2 receptors expressed on ILC2 (5). The underlying inflammatory pathways (endotype and subendotypes), observable features (phenotypes), and biological markers reflecting T2 inflammation are shown in Figure 1 .

As a result, studies on asthma phenotypes and endotypes have gained momentum in recent years. There are no more simple distinctions in asthma such as intrinsic and extrinsic asthma. Understanding asthma phenotypes, endotypes, and biomarkers that reflect them has become even more important as many biologic treatments have begun to offer a targeted approach aimed at treating underlying inflammation in asthma.

High prevalence of pulmonary sequelae at 3 months after hospital discharge in mechanically ventilated survivors of COVID-19

Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations

ATS statement: guidelines for the six-minute walk test

Quantitative computed tomography detects air trapping due to asthma